أرسل هذا في رسالة قصيرة: Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

 _    _      ___     __   __     ___              
| || | ||   / _ \\   \ \\/ //   / _ \\    ____    
| || | ||  | / \ ||   \   //   / //\ \\  |    \\  
| \\_/ ||  | \_/ ||   / . \\  |  ___  || | [] ||  
 \____//    \___//   /_//\_\\ |_||  |_|| |  __//  
  `---`     `---`    `-`  --` `-`   `-`  |_|`-`   
                                         `-`